TRANSMITTAL FORM (to be used for all correspondence after initial filing) Total Number of Pages in This Submission		ent and Trademark Office; U.S. (PTO/SB/21 (08-03) ugh 08/30/2003. OMB 0651-0031 DEPARTMENT OF COMMERCE avs a valid OMB control number.
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Add Terminal Disclaimer Request for Refund CD, Number of CD(s) emarks	After Allow to Technol to Technol Appeal Co of Appeal Co (Appeal No Proprietary Status Let	losure(s) (please elow): PTO/SB08B (2)
Firm or Individual name Signature Date March 26, 2004	e addressed to: Commissioner for P	N/MAILING or deposited with the United	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of)
Joseph L WITZTUM) FOR: METHODS FOR DIAGNOSING,) IMAGING AND TREATING) ATHEROSCLEROTIC DISEASE
Serial No.: 10/705,448) ATHEROSCLEROTIC DISEASE)) Group
Filed: November 11, 2003) Art Unit: unknown

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

Mail Stop DD Commissioner for Patents P.O. Box 1451 Alexandria, VA 22313-1450

Attention:

Examiner

Dear Sir:

Applicants submit herewith references of which they are aware, which they believe may be material to patentability of the invention disclosed and claimed in the above-cited application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: P.O. Box 1450 Alexandria VA 22313-1450:
March 26, 2004
(Mailing Date)
Cindy Guido
Cindu Quide
(Signature)
March 26, 2004
(Date of Signature)

Applicants are submitting herewith copies of the references which are set forth on the attached Form PTO/SB/08A. As all relevant parts of the references are in the English language, no explanation of the references is provided herein.

This Information Disclosure Statement is submitted within three (3) months of the filing date of the above-cited application or of the date of entry into the national phase of the application or prior to the mailing date of a first Office Action thereon, whichever has occurred last, such that no fee is required.

Further, while the references provided in this Information Disclosure Statement may be material to patentability pursuant to 37 C.F.R. § 1.56, it is not intended to constitute an admission that any reference referred to herein is prior art for this invention unless specifically designated as such.

Also, in accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. § 1.56(a) exists.

Respectfully submitted,

Dated: 3/26/04

Bv:

Colleen McKiernan
Agent for Applicant
Registration No. 48,570

GORDON & REES LLP 1660 Union Street San Diego, California 92101

Telephone: (619) 238-0999 Facsimile: (619) 238-0062

Docket No.: 6627-P0045C

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE ne Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known					
Application Number	10/705,448				
Filing Date	11/11/2003				
First Named Inventor	WITZTUM et al				
Art Unit	unknown				
Examiner Name	unknown	• .			
Attorney Docket Number	6627-P0045C				

· ·			U. S. PATENT	DOCUMENTS		
Examiner Cite Initials* No.1		Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	1	^{US-} 5,330,910	7-19-1994	Young et al	whole document	
	2	^{US-} 5,460,947	10-24-1995	Young et al	whole document	
,	3	^{US-} 6,375,925		Witztum et al	whole document	
		US-				
		US-				
		US-				
		US-				
**		US-				
		US-				
		US-				
		US-		,		
		US-				
		US-				
		US-				
		US-				
-		US-				
		ÜS-	<u> </u>			
		US-				
		US-				

	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear
·	4	WO/98/21581	5-22-1998	Tsimikas et al	whole document
	5	WO 94/23302	10-13-1994	Selley	whole document
	<u> </u>				

Examiner	Date	
Signature	Considered	
		1

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			COL 1990, NO persons ar	Complete if Known		
Jubstitu	10 10 10 m 1443/1-10			Application Number	10/705,448	
INFO	ORMATION	DIS	CLOSURE	Filing Date	11/11/2003	
STA	STATEMENT BY APPLICANT			First Named Inventor	WITZTUM et al	
	(lles so mony sho	a t a aa m	accessed.	Art Unit	unknown	
(Use as many sheets as necessary)			ecessary)	Examiner Name	unknown	
Sheet	2	of	3	Attorney Docket Number	6627-P0045C	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	6	Hoorko S. Miller, E. Dudl E. et al Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids:recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized LDL. J. Clin. Invest.;1996:98; 815-825	
	7	Huse WD, Sastry L, Iverson SA, Klang AS, Alting-Mees M, Burton DR, Benkovic SJ, Lerner RA. Generation of a large combinatorial library of immunoglobulin repertoire in phage lambda. Science . 1989;246:1275-1281	
	8	Palinski W. Horkko, S. Miller et al. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins for apo E-deficient mice. Demostration of epitopes of oxidezed LDL in human plasma. J.Clon.Invest 1996;98:800-814	
	9	Shaw P.X, Horkko, S. Chang, M-K Curtiss, L.K. Palinski, W. Silverman, G.J. and Witztum, J.L. Natural antibodies with T15 idiotype may act in atheosclerosis, apoptotoc clearance and protective immunity. J. Clin, Invest. 105:1731-40, 2000	
,	10	Wu CC, Chang SW, Chen MS, Lee YT. Early change of vascular permeability in hypercholoesterloemic rabbits. Arterioscler Thomb Vasc Biol. 1995, 15-529-533	
	11	Libby P. et al. Stabilizing of atherosclerotic plaques: New mechanisms and clinical targets. Nature Medicine. Vol 8, No. 11, 1257-1262-Nov. 2002	
	12	Narula, J. et al. Strategic targeting of atherosclerotic lesions. Journal of Nucelar Cardiology, Part 1, pp. 81-90 Jan./Feb 1999	
	13	Strauss, H.W. Imaging of atheosclerosis-A worthy challenge. Journal of Nucelar Cardiology, Vol 3, No 3, pp.278-280 May/June 1996	
	14	Tsimikas, S. et al. In vivo uptake of Radiolabeled MDA2, an oxidation-specific monoclonal antibody provides an accurate measureArterioscler Thromb, Vasc. Biol., Vol 20:689-697.2006	
	15	Holovet, P. et al, Monodialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J. Clin Invest. Vol 95:2611-9. 1995	

Examiner		Date	
Signature	,	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO		Complete if Known			
Cubstitu	10 10 10 11 14 10 10			Application Number	10/705,448
INF	ORMATION	DIS	CLOSURE	Filing Date	11/11/2003
STA	TEMENT B	SY A	PPLICANT	First Named Inventor	WITZTUM et al
	(Use as many she	ote oc s	occesand	Art Unit	unknown
	(Use as many sne	0 15 85 11	ocessary)	Examiner Name	unknown
Sheet	3	of	3	Attorney Docket Number	6627-P0045C

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	16	Tsimikas S. Palinski W, Halpern SE, Yeung DW, Curtiss LK, Witztum JL. Radiolabeled MDA2, an oxidation-specific Mab, identifies native atherosclerotic lesions in vivo. J. Nucl Cardiol. 1999; 6:41-53	
	i		

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.